Tisotumab vedotin for advanced vulvar cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a drug called tisotumab vedotin for vulvar cancer that has spread or come back. The drug targets a protein on cancer cells to stop them from growing. You may join if you have had only up to 2 prior treatments and are not eligible for curative therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have vulvar cancer that has spread or come back, and it must be the squamous cell type.
- You must not have received more than 2 prior treatments for your advanced vulvar cancer.
- Curative treatments like surgery or radiation should not be an option for you.
- Your cancer must be measurable on a scan (at least 10 mm for a non-lymph node or 15 mm for a lymph node).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
This trial tests a combination of two new drugs—becotatug vedotin (targeted therapy) and zimberelimab (immunotherapy)—in people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if this combination works after standard treatments like platinum chemotherapy and immunotherapy have been tried.
This trial studies how well carboplatin plus paclitaxel chemotherapy works for vulvar squamous cell cancer that has spread. It may help shrink tumors and control cancer growth in people who are not able to be fully treated with local surgery.
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
Hear when a new Vulvar Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.